Diabetes drug no better than placebo for MACE, trial shows
But results of the VERTIS CV trial confirm that ertugliflozin cuts admissions for heart failure
AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.
A trial of ertugliflozin in patients with type 2 diabetes (T2DM) and established atherosclerotic CVD has found no difference in outcomes for major adverse cardiac events (MACE) between the drug and placebo, researchers report.
But the VERTIS CV trial does confirm earlier findings of a reduced risk of admission for heart
